Status:
NOT_YET_RECRUITING
Can we Use a Simple Blood Test to Reduce Unnecessary Adverse Effects From Radiotherapy by Timely Identification of Radiotherapy-resistant Rectal Cancers? MeD-Seq Rectal Study
Lead Sponsor:
Erasmus Medical Center
Conditions:
Pathological Response Rate, Circulating Tumour DNA
Eligibility:
All Genders
18+ years
Brief Summary
Chemoradiation therapy (CRT) followed by surgery is currently the standard of care to treat patients with locally advanced rectal cancer (LARC). CRT reduces local recurrences, but is associated with s...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Histologically confirmed rectal adenocarcinoma
- Scheduled for neoadjuvant chemoradiation
- Written informed consent.
Exclusion
- Scheduled to another neoadjuvant schedule that comprises systemic chemotherapy or short-course radiation
- Not able to read or understand Dutch language or mentally not capable.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT06035471
Start Date
October 1 2023
End Date
June 1 2027
Last Update
September 13 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.